Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.84 (market cap $753.07M), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 11.2× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 57 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FEPI | HNGE | |
|---|---|---|
Market Cap | $753.07M | $8.47B |
Volume | 329,956 | 1,624,526 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $105.14 |
52-Week Low | $37.98 | $31.17 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.28, showing minimal daily movement with a 0.14% gain. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per share. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights FEPI's 25% yield but notes underperformance compared to peers in total returns.
FEPI offers high income potential through its covered call strategy but faces capped upside and concentrated tech exposure risks. The ETF's performance depends heavily on AI sector volatility and options pricing efficiency. While attractive for income-focused investors, total return potential may lag broader market indices during strong bull markets.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
